The US first-approver advantage over the European Union remains stark, with eight of ten novel agents first cleared by the US Food and Drug Administration, according to a Pink Sheet analysis of recent novel approvals by the FDA and European Medicines Agency.
Key Takeaways
-
The FDA and European Union’s novel approvals in 2023 through April 2024 included 48 drugs cleared in both regions and 37 approved by the FDA first.








